CIONC - Centro Integrado de Oncologia de Curitiba
Curitiba, Brazil
Doctor in Curitiba, State of Paraná
Rua Desembargador Vieira Cavalcanti, 1152 - Mercês, Curitiba - PR, 80810-050
About CIONC - Centro Integrado de Oncologia de Curitiba
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Janssen Research & Development, LLC
6
Arcus Biosciences, Inc.
1
Clinical Trials at CIONC - Centro Integrado de Oncologia de Curitiba
During the past decade, CIONC - Centro Integrado de Oncologia de Curitiba conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
2016-11-30
2022-12-12
Completed
1,005
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
2019-01-25
2027-02-19
Active, not recruiting
765
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
2019-04-22
2022-11-29
Completed
14,532
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
2019-10-10
2023-07-07
Recruiting
3,160
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
2020-09-30
2029-09-01
Recruiting
190
A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
2020-10-08
2028-06-30
Active, not recruiting
214
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
2020-09-23
2027-05-07
Recruiting
692
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
2020-08-24
2027-12-30
Active, not recruiting
800
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "CIONC - Centro Integrado de Oncologia de Curitiba"
#1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at CIONC - Centro Integrado de Oncologia de Curitiba
According to Clinical.Site data, the most researched conditions in "CIONC - Centro Integrado de Oncologia de Curitiba" are
"Carcinoma, Non-Small-Cell Lung" (2 trials), "Paroxysmal Nocturnal Hemoglobinuria" (2 trials), "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Castration-Resistant Prostatic Cancer" (1 trials) and "Esophageal Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "CIONC - Centro Integrado de Oncologia de Curitiba" in a lesser frequency.
Clinical Trials Intervention Types at CIONC - Centro Integrado de Oncologia de Curitiba
Most popular intervention types in "CIONC - Centro Integrado de Oncologia de Curitiba" are "Drug" (12 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (3 trials), "Amivantamab" (2 trials), "Carboplatin" (2 trials), "Crovalimab" (2 trials) and "Eculizumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at CIONC - Centro Integrado de Oncologia de Curitiba
The vast majority of trials in "CIONC - Centro Integrado de Oncologia de Curitiba" are
10 trials for "All" genders and 3 trials for "Male" genders.
Clinical Trials Status at CIONC - Centro Integrado de Oncologia de Curitiba
Currently, there are NaN active trials in "CIONC - Centro Integrado de Oncologia de Curitiba".
undefined are not yet recruiting,
8 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in CIONC - Centro Integrado de Oncologia de Curitiba,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in CIONC - Centro Integrado de Oncologia de Curitiba, 1 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 11 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".
Departments of CIONC - Centro Integrado de Oncologia de Curitiba
CIONC - Centro Integrado de Oncologia de Curitiba has several departments that took part in Clinical trials: "Centro Integrado de Oncologia de Curitiba" - 3 trials
Departments List
Name
City
Trials